The global central venous catheter market is on a strong upward trajectory, with projections indicating a rise from USD 2,861.0 million in 2024 to a remarkable USD 5,436.8 million by 2034. This growth ...

The global cardiac rhythm remote monitoring devices market is experiencing a strong growth surge, projected to reach USD 7,985.6 million by 2033, up from USD 4,782.1 million in 2023. This expansion ...

The global blood cancer treatment market is on a dynamic growth trajectory, projected to climb from approximately USD 7,065.4 million in 2025 to around USD 18,729.4 million by 2035, marking a ...

The global dissolving microneedle market value is expected to rise from USD 47.2 million in 2024 to USD 118.5 million by 2034. This estimated growth is expected to be driven by a promising CAGR of ...

The global medical cleaning devices market is poised for transformative growth, with projections estimating its valuation to surge from USD 28,462.09 million in 2025 to an impressive USD 75,861.59 ...

The global ligament augmentation market is on a significant growth trajectory, projected to grow from USD 51.15 million in 2025 to approximately USD 84.12 million by 2035, reflecting a CAGR of 5.1% ...

Sartorius Stedim Biotech SA / Key word (s): Quarter Results/Forecast Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 16-Apr-2025 / 07:00 CET/CEST Sales revenue at 745 ...

MURFREESBORO, TN / ACCESS Newswire / April 15, 2025 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the first quarter ended March 31, 2025. NHI plans ...

Annual Report/Annual ResultsPentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year 15.04.2025 / 08:17 CET/CESTThe issuer is solely responsible ...

VANCOUVER, BC / ACCESS Newswire / April 15, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that Company completed its previously ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.